Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Michal Haran

A Phase I-Ii Clinical Trial of the Anti-Cd74 Monoclonal Antibody Milatuzumab in Frail Patients With Refractory Chronic Lymphocytic Leukaemia: A Patient Based Approach

British Journal of Haematology

Hematology

2017

English

2.1 CD84 Is a Survival Receptor for CLL Cells

Clinical Lymphoma, Myeloma and Leukemia

English

Related publications

A Phase II Trial of Eltrombopag for Patients With Chronic Lymphocytic Leukaemia (CLL) and Thrombocytopenia

British Journal of Haematology

Hematology

2018

English

Safety and Efficacy of Ofatumumab, a Fully Human Monoclonal Anti-Cd20 Antibody, in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: A Phase 1-2 Study

English

Stomach Cancer in a Patient With Chronic Lymphocytic Leukaemia

Creative surgery and oncology

2019

English

Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study

Clinical Lymphoma, Myeloma and Leukemia

English

A Phase I/Ii Trial of TLR-7 Agonist Immunotherapy in Chronic Lymphocytic Leukemia

English

Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies

Journal for ImmunoTherapy of Cancer

English

A Phase I/Ii Study of Rituximab and Etanercept in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

English

A Phase I Study of Farletuzumab, a Humanized Anti-Folate Receptor Α Monoclonal Antibody, in Patients With Solid Tumors

Investigational New Drugs

Oncology

Pharmacology

2014

English

A Phase 1 Study of Anti-TGFβ Receptor Type-Ii Monoclonal Antibody LY3022859 in Patients With Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Michal Haran

A Phase I-Ii Clinical Trial of the Anti-Cd74 Monoclonal Antibody Milatuzumab in Frail Patients With Refractory Chronic Lymphocytic Leukaemia: A Patient Based Approach

2.1 CD84 Is a Survival Receptor for CLL Cells

Related publications

A Phase II Trial of Eltrombopag for Patients With Chronic Lymphocytic Leukaemia (CLL) and Thrombocytopenia

Safety and Efficacy of Ofatumumab, a Fully Human Monoclonal Anti-Cd20 Antibody, in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: A Phase 1-2 Study

Stomach Cancer in a Patient With Chronic Lymphocytic Leukaemia

Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study

A Phase I/Ii Trial of TLR-7 Agonist Immunotherapy in Chronic Lymphocytic Leukemia

Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies

A Phase I/Ii Study of Rituximab and Etanercept in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

A Phase I Study of Farletuzumab, a Humanized Anti-Folate Receptor Α Monoclonal Antibody, in Patients With Solid Tumors

A Phase 1 Study of Anti-TGFβ Receptor Type-Ii Monoclonal Antibody LY3022859 in Patients With Advanced Solid Tumors